MGMariano Galdiero

Mariano Galdiero

*This is an algorithmically generated author record based on publicly available information.

Mariano Galdiero has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia

    by Renata Simona Auriemma, Chiara Blasio, Ludovica Francesca Stella Grasso, Mariano Galdiero, Mariarosaria Negri, Claudia Pivonello, Luciana Granieri, Annamaria Colao, Rosario Pivonello

    Hyperprolactinemia is associated with abnormalities in glucose and lipid profile with development of insulin resistance and metabolic syndrome (MetS), which have been found to be improved by treatment with cabergoline (CAB). The current study aimed at investigating hormonal and metabolic effects of long-term CAB withdrawal in patients with prolactinomas. In 46 patients (37 F, 9 M, aged 34.5±11.5 yrs, 36 microadenomas and 10 macroadenomas) anthropometric (weight, BMI, waist circumference (WC)) and metabolic (fasting glucose (FG) and insulin (FI), total (TCHO), HDL and LDL cholesterol, triglycerides (TG), HOMA-IR, HOMA-β, ISI0, VAI, and prevalence of MetS) parameters, and PRL levels were evaluated at baseline, at CAB withdrawal (TWD), and 12 (T12) and 60 (T60) months after CAB discontinuation. CAB treatment (median duration=72 months) induced PRL normalization in all patients, and a significant improvement of BMI (PPP=0.007), HDL (PPP=0.012) and ISI0 (P=0.05) compared to baseline. CAB withdrawal resulted in prolonged and sustained normoprolactinemia, with only 8 (17.4%) patients requiring treatment restarting within 12 months. In 38 patients permanently discontinuing CAB, compared to TWD BMI (PPPPPPPPP<0.0001), with 8 patients (17.4%) developing MetS after CAB withdrawal. In conclusion, CAB discontinuation significantly worsens lipid profile and MetS prevalence in patients with prolactinomas.

  • Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

    by Renata S. Auriemma, Ludovica F. S. Grasso, Mariano Galdiero, Maurizio Galderisi, Claudia Pivonello, Chiara Simeoli, Maria Cristina De Martino, Rosario Ferrigno, Mariarosaria Negri, Cristina de Angelis, et al.

    To date, no data are available on the effects of long-term combined treatment with somatostatin analogues (SA) and pegvisomant (PEG) on cardiovascular complications in acromegaly. The current study aimed at investigating the effects of long-term SA + PEG on cardiac structure and performance. Thirty-six patients (14 M, 22 F, aged 52.3 ± 10.2 years) entered this study. Weight, BMI, systolic (SBP) and diastolic (DBP) blood pressure, IGF-I, fasting glucose (FG), fasting insulin (FI), HOMA-IR, HbA1c, and lipids were evaluated at baseline (T0), after long-term (median 36 months) SA (T1), after 12 (T12) and 60 (T60) months of SA + PEG, and at last follow-up (LFU, median 78 months). At each time point, all patients underwent echocardiography. At T1, induced a slight but not significant decrease in IGF-I (p = 0.077), whereas FI (p = 0.004), HOMA-IR (p = 0.013), ejection fraction (EF, p = 0.013), early (E) to late (A) ventricular filling velocities (E/A, p = 0.001), and isovolumetric relaxation time (IVRT, p = 0.000) significantly improved. At T12, IGF-I (p = 0.000) significantly reduced compared to T0, and FI (p = 0.001), HOMA-IR (p = 0.000), LVMI (p = 0.000), and E/A (p = 0.006) further improved compared to T1. At T60, FI (p = 0.027), HOMA-IR (p = 0.049), and E/A (p = 0.005) significantly improved as compared to T1. At LFU IGF-I normalized in 83.3 %, FI (p = 0.000), HOMA-IR (p = 0.000), LVMi (p = 0.000), and E/A (p = 0.005) further improved as compared to T1. PEG dose significantly correlated with LVMi at T12 (r = 0.575, p = 0.000) and T60 (r = 0.403, p = 0.037). Long-term PEG addition to SA improves cardiac structure and performance, particularly diastolic dysfunction, in acromegalic patients resistant to SA.


  • Open Access

    The role of dopamine pathway on human sperm: in vitro effect of dopamine receptor agonists and antagonists on sperm motility, kinetics and viability

    by Angelis Cristina de, Federica Cariati, Giacomo Galdiero, Giorgio Coppola, Mariano Galdiero, Ciro Salzano, Claudia Pivonello, Roberta Patalano, Carlo Alviggi, Placido Giuseppe De, et al.

    Dopamine has been found in both semen and oviductal fluid and dopamine receptors (DRs) have been detected in male genital tract and spermatozoa, suggesting that dopamine system may control important reproductive functions in humans. Dopamine improves sperm motility and viability in animal models, although the underlying molecular mechanisms have not been fully elucidated. The aims of this study were to investigate DRs expression in human spermatozoa and to evaluate the in vitro effects of DRs agonists and antagonists on human sperm motility, kinetics and viability. DRs expression was assessed by immunofluorescence and western blot in spermatozoa from healthy volunteers and the effects of D2DR-like agonist cabergoline, D2DR-selective antagonist L-sulpiride, D4DR-selective agonist PD168,077 and D4DR-selective antagonist U-101958 on sperm motility, kinetics and viability were tested after 1 hour of treatment with serial doses of compounds. Sperm motility and kinetics were analyzed by Sperm Class Analyzer [SCA] 5.0, sperm viability was assessed by Vital Stain Dye. D2DR and D4DR are both expressed in human spermatozoa. Cabergoline significantly increased rapid progressive motile spermatozoa (RPMS) and decreased non motile spermatozoa (NMS). L-sulpiride showed opposite, although not significant, effects on sperm motility. PD168,077 and U-101958 did not significantly change sperm motility. Moreover, L-sulpiride significantly decreased curvilinear velocity (VCL) and increased wobble (WOB). All tested compounds did not affect sperm viability. Both cabergoline and PD168,077 induced Akt phosphorylation, compared to untreated spermatozoa. The results of the current study demonstrated that dopamine pathway may be involved in the modulation of human sperm motility and kinetic parameters, without affecting sperm viability, and that Akt could be regarded as a putative mediator; however, further experiments are being performed to identify the molecular mechanisms driving these effects.


  • Thyroid diseases in the 'Land of Fires': results of a single center screening in Acerra (Naples)

    by Auriemma Renata Simona, Mariaconcetta Cozzolino, Arturo Belli, Gaetano Fierro, Gaetana Messina, Luca Renato De, Simone Teresa De, Matteo Rivezzi, Mariano Galdiero, Angelis Cristina de, et al.

    Introduction: Environmental toxins, including those deriving from illegal and hazardous disposal of urban and chemical waste, are known to act as endocrine disruptors and to increase the risk of malignancy and cancer mortality. The present study aimed at investigating prevalence and characteristics of thyroid diseases in the area of Acerra, a town in the perimeter of the so called ‘Land of Fires’. Methods: The screening included subjects aged ≥15 yrs living in Acerra. Overall, 787 consecutive subjects (631 F, 156 M, aged 39.6±16.3 yrs) were recruited on a voluntary basis. Iodine supplementation, thyroid palpation, hormonal testing (TSH, fT3, fT4, antithyroid antibodies), ultrasound and fine needle cytology (FNC, when necessary) were investigated. According to the age tertiles, subjects were classified as Group A (age 52 yrs, no=241). Results: Prevalence of Hashimoto’s thyroiditis and nodular goiter was 13.5% and 17.5% of the whole cohort, respectively, being not different as compared to that of the Italian general population. Hashimoto’s thyroiditis was significantly prevalent in C compared to A (P=0.021), and hyperthyroidism in C compared to A (P=0.003) and B (P=0.03). Prevalence of nodular goiter was higher in C as compared to A (PPP=0.032) as compared to those who did. Among subjects undergone FNC, none had thyroid cancer and all were classified as benign nodular disease (THY2). Conclusion: These findings suggest that subjects living in the area of Acerra had a similar prevalence of thyroid diseases as compared to the Italian general population and did not present with an increased prevalence of thyroid cancers despite chronic exposure to environmental pollutants.

    • 21 October 2015
      • Vol. 32  (5)

    [Chronic kidney disease: fertility and sexuality].

    by Mariano Galdiero, Ciro Salzano, Annamaria Colao, Rosario Pivonello

  • Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

    by Renata S Auriemma, Ludovica F S Grasso, Mariano Galdiero, Claudia Pivonello, Ciro Salzano, Mariarosaria Negri, Cristina de Angelis, Annamaria Colao, Rosario Pivonello

    Somatostatin analogues (SA) are known to revert acromegalic cardiomyopathy mainly in young patients with short disease duration, whereas pegvisomant (PEG) reportedly improves cardiac structure and performance in patients resistant to SA. To date, no data are available on the effects of long-term SA+PEG on cardiovascular complications. The current study aimed at investigating the effects of long-term SA+PEG on cardiac structure and performance in acromegaly. Thirty-six acromegalic patients (14M, 22F, aged 52.3±10.2 years) entered the study. Weight, BMI, systolic (SBP) and diastolic (DBP) blood pressure, IGF1, fasting glucose (FG), fasting insulin (FI), HOMA-IR, HbA1c and lipids were evaluated at diagnosis (T0), after long-term (median 36 months, range 6–156 months) SA (T1), and after 12 (T12) and 60 (T60) months of SA+PEG, with last follow up (LFU) being performed after a median time of 78 months (range 60–144 months). At each time point all patients underwent echocardiography. SA induced a slight but not significant decrease in IGF1 (P=0.077), whereas FI (P=0.004), HOMA-IR (P=0.013), ejection fraction (EF, P=0.013), early (E) to late (A) ventricular filling velocities (E/A, P=0.001) and isovolumetric relaxation time (IVRT, P=0.000) significantly improved. At T12 weight (P=0.004), BMI (P=0.005), IGF1 (P=0.000), FI (P=0.001), HOMA-IR (P=0.000), left ventricular mass index (LVMi, P=0.000) and E/A (P=0.006) significantly improved compared to T0, with HOMA-IR further improving (P=0.000) compared to T1. At T60, IGF1 (P=0.000), FI (P=0.001), HOMA-IR (P=0.000), E/A (P=0.05) and IVRT (P=0.014) significantly ameliorated compared to T0. At LFU IGF1 normalized in 83.3%; IGF1 (P=0.000), FG (P=0.043), FI (P=0.000), HOMA-IR (P=0.000), HDL (P=0.031), EF (P=0.035), LVMi (P=0.000), E/A (P=0.02) and IVRT (P=0.001) significantly improved compared to T0. PEG dose significantly correlated with LVMi at T12 (r=0.575, P=0.000) and T60 (r=0.403, P=0.037). In conclusion, long-term PEG addition to SA improves cardiac structure and performance, particularly diastolic dysfunction, in acromegalic patients resistant to SA.


  • Open Access

    Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease

    by Francesco Lotti, Vincenzo Rochira, Rosario Pivonello, Daniele Santi, Mariano Galdiero, Elisa Maseroli, Antonio Balestrieri, Marco Faustini-Fustini, Alessandro Peri, Alessandra Sforza, et al.

    The prevalence of erectile dysfunction (ED) and its correlates in men with acromegaly has never been investigated. The aim of this study was to evaluate sexual function in men with acromegaly. Multicenter-based, retrospective analysis of a nonselected series of 57 acromegalic subjects (mean age: 52.7 ± 14.2 years) was performed. Acromegalic subjects reporting ED (n = 24) were compared with matched ED patients without acromegaly or pituitary disease (controls), selected from a cohort of more than 4,000 subjects enrolled in the Florence Sexual Medicine and Andrology Unit. Patients were interviewed using Structured Interview on Erectile Dysfunction (SIEDY) structured interview, a 13-item tool for the assessment of ED-related morbidities. Several clinical and biochemical parameters were taken. Penile color Doppler ultrasound (PCDU) was performed in a subgroup of 37 acromegalic subjects. ED was reported by 42.1% of acromegalic subjects. After adjusting for age and testosterone, acromegalic subjects with ED had a higher prevalence of hypertension and more often reported an impairment of sleep-related erections and a longer smoking habit. Accordingly, acromegaly-associated ED was characterized by a higher organic component and worse PCDU parameters. No relationship between ED and testosterone levels or other acromegaly-related parameters was found. However, acromegalic subjects with severe ED reported a longer disease duration. In a case-control analysis, comparing acromegalic subjects with ED-matched controls free from acromegaly (1:5 ratio), acromegalic men had a worse ED problem and a higher organic component of ED, as derived from SIEDY score. In line with these data, acromegalic patients with ED had a higher prevalence of major adverse cardiovascular events history at enrollment and lower PCDU parameters. Subjects with complicated acromegaly are at an increased risk of developing ED, especially those with cardiovascular morbidities. Our data suggest including a sexual function evaluation in routine acromegaly follow-up. Lotti F, Rochira V, Pivonello R, Santi D, Galdiero M, Maseroli E, Balestrieri A, Faustini-Fustini M, Peri A, Sforza A, Colao A, Maggi M, and Corona G. Erectile dysfunction is common among men with acromegaly and is associated with morbidities related to the disease. J Sex Med 2015;12:1184–1193.


  • Open Access

    Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas

    by Renata S. Auriemma, Mariano Galdiero, Pasquale Vitale, Luciana Granieri, Fabio Lo Calzo, Ciro Salzano, Lucia Ferreri, Claudia Pivonello, Federica Cariati, Giorgio Coppola, et al.

    Introduction: Hyperprolactinemia and hypogonadism are reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of testosterone replacement and cabergoline (CAB) treatment on the metabolic profile in male hyperprolactinemic patients. Patients and Methods: Thirty-two men with prolactinomas, including 22 with total testosterone (TT) 8 nmol/l (non-HG, 31%), were entered in the study. In all patients, metabolic parameters were assessed at diagnosis and after 12- and 24-month treatment. Results: Compared to non-HG patients, at baseline the HG patients had higher waist circumference (WC). TT significantly correlated with body mass index (BMI). Twelve-month CAB induced PRL normalization in 84%. HG prevalence significantly decreased (28%) and non-HG prevalence significantly increased (72%). Anthropometric and lipid parameters, fasting insulin (FI), insulin sensitivity index (ISI₀), homeostatic model assessment of insulin secretion (HOMA-β) and homeostatic model assessment of insulin resistance (HOMA-IR) significantly improved compared to baseline. TT was the best predictor for FI. Percent change (Δ) of TT significantly correlated with ΔCholesterol, ΔWeight and ΔBMI. Compared to non-HG patients, the HG patients had a higher weight, BMI, WC and HOMA-β. In HG, testosterone replacement was started. After 24 months, PRL normalized in 97%. HG prevalence significantly decreased (6%) and non-HG prevalence significantly increased (94%). Anthropometric and lipid parameters, FI, ISI₀, HOMA-β and HOMA-IR significantly improved compared to baseline, with FI, ISI₀, HOMA-β and HOMA-IR further ameliorating compared to the 12-month evaluation. Compared to non-HG patients, the HG patients still had a higher weight, BMI and WC. Conclusions: In hyperprolactinemic hypogonal men, proper testosterone replacement induces a significant improvement in the metabolic profile, even though the amelioration in the lipid profile might reflect the direct action of CAB.


  • Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism

    by Mariano Galdiero, Renata S Auriemma, Pasquale Vitale, Fabio Lo Calzo, Ciro Salzano, Lucia Ferreri, Federica Cariati, Giorgio Coppola, Annamaria Colao, Rosario Pivonello

    Hyperprolactinemia is reportedly associated with impaired metabolic profile, particularly in patients with concomitant hypogonadism. The current study aimed at investigating the effects of 12 and 24 month-continuous cabergoline (CAB) treatment on metabolic profile in male hyperprolactinemic patients. Thirty-two men with prolactinomas, including 22 with testosterone < 8 nmol/l (HG, 69%) and 10 with T > 8 nmol/l (non–HG, 31%) entered the study. In all patients, metabolic parameters were assessed at diagnosis and after CAB treatment. Compared to non-HG, at baseline HG patients had higher PRL and waist circumference (WC). Testosterone significantly correlated with BMI. Metabolic syndrome (MetS) prevalence was not significantly different in HG (60%) and non-HG (45.4%). 12-month CAB induced PRL normalization in 91% of patients. HG prevalence significantly decreased (28%) and non-HG prevalence significantly increased (72%). Lipid and anthropometric parameters, as well as fasting insulin (FI), ISI0, HOMA-beta, HOMA–IR and VAI were all significantly improved compared to baseline. Testosterone was the best predictive factor for FI. Testosterone percent change (Δ) significantly correlated with ΔCholesterol (CHO), ΔWeight and ΔBMI. Compared to non-HG, HG patients had higher weight, BMI, WC and HOMA-β. MetS prevalence did not differ in HG (33%) and non-HG (13%). In HG, testosterone replacement was started. After 24 month-CAB, PRL normalised in 97% of cases. HG prevalence significantly decreased (6%) and non-HG prevalence significantly increased (94%). Lipid and anthropometric parameters, as well as FI, ISI0, HOMA-beta and HOMA-IR were all significantly improved compared to baseline, with FI, ISI0, HOMA-beta and HOMA–-IR also significantly ameliorating compared to 1-year evaluation. Compared to non-HG, HG patients still had higher weight, BMI and WC. MetS prevalence did not differ in HG (11%) and non-HG (13%). In conclusion, in hyperprolactinemic hypogonal men proper replacement of testosterone deficiency induces a significant improvement in metabolic profile, even though the amelioration in lipid profile might reflect the direct action of CAB.